<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Merck.com</provider_name><provider_url>https://www.merck.com</provider_url><author_name>whartoky</author_name><author_url>https://www.merck.com/author/whartoky/</author_url><title>Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir - Merck.com</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="kex3GqFRDU"&gt;&lt;a href="https://www.merck.com/news/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir/"&gt;Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.merck.com/news/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir/embed/#?secret=kex3GqFRDU" width="600" height="338" title="&#x201C;Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir&#x201D; &#x2014; Merck.com" data-secret="kex3GqFRDU" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/*! This file is auto-generated */
!function(c,d){"use strict";var e=!1,o=!1;if(d.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},!c.wp.receiveEmbedMessage)if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(t)if(t.secret||t.message||t.value)if(!/[^a-zA-Z0-9]/.test(t.secret)){for(var r,a,i,s=d.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),n=d.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),o=0;o&lt;n.length;o++)n[o].style.display="none";for(o=0;o&lt;s.length;o++)if(r=s[o],e.source===r.contentWindow){if(r.removeAttribute("style"),"height"===t.message){if(1e3&lt;(i=parseInt(t.value,10)))i=1e3;else if(~~i&lt;200)i=200;r.height=i}if("link"===t.message)if(a=d.createElement("a"),i=d.createElement("a"),a.href=r.getAttribute("src"),i.href=t.value,i.host===a.host)if(d.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener("message",c.wp.receiveEmbedMessage,!1),d.addEventListener("DOMContentLoaded",t,!1),c.addEventListener("load",t,!1);function t(){if(!o){o=!0;for(var e,t,r,a=-1!==navigator.appVersion.indexOf("MSIE 10"),i=!!navigator.userAgent.match(/Trident.*rv:11\./),s=d.querySelectorAll("iframe.wp-embedded-content"),n=0;n&lt;s.length;n++){if(!(r=(t=s[n]).getAttribute("data-secret")))r=Math.random().toString(36).substr(2,10),t.src+="#?secret="+r,t.setAttribute("data-secret",r);if(a||i)(e=t.cloneNode(!0)).removeAttribute("security"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:"ready",secret:r},"*")}}}}(window,document);
&lt;/script&gt;
</html><description>Foster City, Calif. &amp; Kenilworth, N.J.- November 23, 2021 &#x2013; Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, are temporarily pausing enrollment in the Phase 2 clinical study (NCT05052996), evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically [&hellip;]</description><thumbnail_url>https://www.merck.com/wp-content/uploads/sites/5/2022/03/Merck.png</thumbnail_url><thumbnail_width>3056</thumbnail_width><thumbnail_height>1380</thumbnail_height></oembed>
